Illumina Stock Crumbles As Earnings Guidance Completely Misses Forecasts

Must read

Late Wednesday, Illumina (ILMN) reported adjusted earnings of 32 cents per share on $1.18 billion in second-quarter sales. In response, ILMN stock plunged.


On average, analysts surveyed by FactSet expected Illumina to earn 2 cents per share and report $1.16 billion in sales.

In the year-earlier period, the DNA-sequencing giant reported 57 cents in earnings per share and had $1.16 billion in sales.

For the year, Illumina predicted adjusted earnings of 75 cents to 90 cents per share and 1% sales growth. ILMN stock analysts predicted earnings of $1.27 a share on nearly $4.9 billion in sales.

The company cautioned sales in the second year will be negatively impacted by customer caution, a slower recovery in China and a larger decline in consumable instruments as customers move to Illumina’s new DNA-reading system, NovaSeq X.

In after-hours trading on the stock market today, ILMN stock dropped 5.9% to 173.70.

More to follow.

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Eli Lilly Has A Big Stake In Weight Loss And Alzheimer’s Drugs; But Is The Stock A Buy?

Mirati Rockets 31% On A Bevy Of News In Cancer, A $300 Million Deal And Its CEO Exit

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks

Learn How To Time The Market With IBD’s ETF Market Strategy

Get Timely Buy & Sell Alerts With IBD Leaderboard

More articles

Latest article